Notizia - Recent Pharma, Healthcare and Biotech Happenings

Historic win for Pfizer's COVID-19 Vaccine; Alexion Buyout; and more

FTA for Gannex’s ASC4; Disappointment for Incyte’s Ruxolitinib; Historic win for Pfizer, BioNTech’s COVID Vaccine; Alexion buyout; the debut of InnoSkel

Gannex received US FDA fast track designation for its NASH drug, ASC42 an FXR Agonist Gannex Pharma has received Fast Track designation approval from FDA for its drug candidate ASC42 for non-alcoholic steatohepatitis (NASH). The FTA designation will help the pharma company to advance its research and development in the NASH landscape and help its commercialization in the market. At present, there are no approved therapies for NASH. The present NASH treatment market is dominated and supported by off-label therapies. DelveInsight estimated that the coming future for NASH market is expected to experience entry of more such off-label therapies unless an approved cur...

Explore More...

Can-Fite Receives Payment; Leafbuyer Technologies and Denver Post’s Cannabist; EPX-300 & JOTROL received Designation; New treatment Approved for adults

Stada’s €5.3B; Pfizer takes 30 cents; GSK, Exscientia ink deal; Trillium hunts for partners; Clementia files for $115M IPO

Market & Competitive Assessment

Market Size & Forecast Assessment

Medical Devices

Market Research

Subscription

Competitive Intelligence

Business Consulting

Customized Solutions

Request for Proposal

Blog

Newsletter/Whitepaper

Infographics

Case Study

Events

Press Release

Analysis & Perspective

Notizia - Recent Pharma, Healthcare and Biotech Happenings

FTA for Gannex’s ASC4; Disappointment for Incyte’s Ruxolitinib; Historic win for Pfizer, BioNTech’s COVID Vaccine; Alexion buyout; the debut of InnoSkel

Business cocktail

Idera’s Phase I Data; DelMar Initiates Trial; Novartis’ study; Humira gets EC approval

CAR-T Phase I trials; ContraVir Announces; Merck acquired; Excision BioTherapeutics bags $10M

Can-Fite Receives Payment; Leafbuyer Technologies and Denver Post’s Cannabist; EPX-300 & JOTROL received Designation; New treatment Approved for adults

Business CockTail

Bristol-Myers Squibb to nix; Pfizer commits $100M; Merck and GSK production issues; Shire unloads plant

Cannabidiol trial; MyoKardia aims; LDL drug data

Allergan sell; AZ, Merck team up; Roche’s MS drug; Chinese API maker receives a warning letter

More Views & Analysis

Remicade’s launch; Endo cuts jobs; Analysts downgrade Pfizer; Corning $500M glass project

Takeda scores; PhRMA launches; Valeant’s Obagi; Ex-Novo executive signs

Gilead faces lawsuit; Herceptin stalled; Lilly revs up, Abemaciclib gets nod; Key Humira patent gets struck down

Stada’s €5.3B; Pfizer takes 30 cents; GSK, Exscientia ink deal; Trillium hunts for partners; Clementia files for $115M IPO

Merck got attack; Stada’s €5.32B; Private equity fund buys; Lonza on $5.5B deal

Takeda knocks Velcade; FDA nod awaited; Novartis gets approval; Astellas UK dodges; Haegarda set for launch

Novartis on AMD drug; Hospira recall of vials; Takeda wraps up; FDA bans imports

J&J nabs; Clovis plots Rubraca; Novartis scores EU approval; Seattle Genetics stops trials

Subscribe to our Updates

Daily

Weekly

Monthly